Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxine-A case report.

Basic & clinical pharmacology & toxicology - 1 Oct 2020

Kuzin Maxim, Scharrer Isabel, Nolan Daniele, Baumgartner Markus, Paulzen Michael, Schoretsanitis Georgios, Xepapadakos Franziskos

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP1A2
Share to Cytochrome P-450 CYP2D6
Share to Depression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Monitoring

Share to Inactivation, Metabolic

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Share to Venlafaxine Hydrochloride

Source

Identifiers

PMID: 32365274
DOI: 10.1111/bcpt.13428

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxine-A case report.PMID 32365274Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.Semantic proximity Read ↗

Effect of CYP2D6 genotype on duloxetine serum concentration.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.Semantic proximity Read ↗

[Importance of genetic polymorphism of cytochrome P450 isoenzymes for the choice and regimes of antidepressant and antipsychotic dosing on an individual basis].Semantic proximity Read ↗

Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms.Semantic proximity Read ↗

The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major DepressionSemantic proximity Read ↗

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.Semantic proximity Read ↗

Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.Semantic proximity Read ↗

The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.Semantic proximity Read ↗

[CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].Semantic proximity Read ↗

Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort study.Semantic proximity Read ↗

Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.